Drug recall · April 29, 2020
Cefixime for Oral Suspension USP recall
Why: Subpotent Drug: low out of specification (OOS) test result observed in long term stability study.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Cefixime for Oral Suspension USP, 100mg/5mL, Rx Only, Manufactured for: Lupin Pharmaceutical, Inc. Baltimore, Maryland 21202 United States, Manufactured by: Lupin Limited Mandideep 462 046 INDIA, NDC 68180-405-01
- Lots / codes
Lot #: F800779, Expiry 4/2020
- Quantity
- 4,518 bottles
- Company
- Lupin Pharmaceuticals Inc., Baltimore, MD
- Distribution
- Nationwide with the United States and Puerto Rico.
- Initiated
- April 15, 2020 · Voluntary: Firm initiated
- Classified
- April 23, 2020
- Reported
- April 29, 2020
- Ended
- June 7, 2021
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Cefixime
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.